(NASDAQ: MPLT) Maplight Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.23%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.06%.
Maplight Therapeutics's earnings in 2026 is -$229,826,000.On average, 16 Wall Street analysts forecast MPLT's earnings for 2026 to be -$231,680,460, with the lowest MPLT earnings forecast at -$251,340,023, and the highest MPLT earnings forecast at -$228,387,634. On average, 16 Wall Street analysts forecast MPLT's earnings for 2027 to be -$191,113,770, with the lowest MPLT earnings forecast at -$220,433,835, and the highest MPLT earnings forecast at -$155,829,516.
In 2028, MPLT is forecast to generate -$187,092,812 in earnings, with the lowest earnings forecast at -$227,251,377 and the highest earnings forecast at -$155,829,516.